



Epidermal growth factor receptor (EGFR) comprises a
dominant signalling pathway for many tumours. In breast
cancer, increased expression of EGFR or its EGF-like
ligands and hyperactivation of subsequent mitogen-acti-
vated protein kinase (MAPK) and protein kinase B (AKT)
signalling have been linked to anti-hormone resistant
growth, metastatic progression and poor prognosis. Con-
siderable data exist detailing EGFR activation and the
downstream signalling that is triggered subsequent to
EGFR ligand binding, allowing rationale design of several
anti-EGFR agents that are currently in clinical trials in
cancers including the breast. However, less is known
about the mechanisms regulating EGF-like ligand availabil-
ity and their potential as therapeutic targets.
EGFR ligands, including transforming growth factor α
(TGFα), heparin-binding EGF (HB-EGF) and amphiregulin
(AR), are expressed as transmembrane precursors. These
are released from the cell surface following shedding of
the extracellular domain (ectodomain shedding) by zinc-
dependent proteinases. The soluble ligand can bind and
activate EGFR in an autocrine or paracrine manner, while
the transmembrane (pro) form may activate EGFR in adja-
cent cells (juxtacrine). Of emerging importance as regula-
tors of EGFR ligand shedding is the ADAM (a disintegrin
and metalloprotease) family of membrane glycoproteins.
This family currently comprises 34 members. However, the
nature of individual ADAMs required for EGFR ligand
shedding, and their role in EGFR activation and its interac-
tion with other signalling pathways, remain poorly defined
in tumour cells. Three new articles examining ADAM17
(TNFα-converting enzyme; TACE) and ADAM10 (Kuzban-
ian) shed light in these areas. Borrell-Pages et al. [1]
establish relevance of TACE to TGFα shedding and
EGFR signalling in clinical breast cancer, while Gschwind
et al. [2] and Yan et al. [3] reveal that TACE and ADAM10
contribute to the interplay between EGFR and diverse sig-
nalling pathways.
ADAM metalloprotease TACE controls TGFα α
shedding in tumours in vivo and associates
with EGFR activation in breast cancer
The new article by Borrell-Pages et al. provides com-
pelling evidence that EGFR activation by TGFα is critically
dependent on ligand shedding in tumours. Interestingly,
shedding not only controls availability of the soluble ligand
but also determines juxtacrine activity of the transmem-
brane form. The ADAM TACE was revealed to be the key
regulator for TGFα shedding in transfected Chinese
hamster ovary (CHO) cells. These data complement previ-
ous in vitro observations that absence of/non-functional
TACE underlies defective TGFα shedding. Excitingly,
Borrell-Pages et al. demonstrated a crucial role for TACE
in tumourigenesis, with TACE-mediated TGFα shedding
being essential for EGFR activation and maximal tumour
development of the transfected CHO cells in vivo. Further-
more, TACE was markedly overexpressed in human breast
cancer, where it directly associated with EGFR activation.
TACE thus appears to be of considerable importance in
regulating EGFR signalling in breast tumours. The prog-
nostic implications of heterogeneity of TACE expression
remain to be addressed. Similarly, monitoring of TACE in
endocrine resistant breast cancer and clinical progression
is required, particularly since metalloprotease-mediated
EGFR ligand shedding regulates breast cancer cell prolif-
eration and migration in vitro [4].
ADAMs contribute to EGFR transactivation by
diverse signalling pathways
Multiple pathways can promote EGFR signalling and
growth by EGFR transactivation. EGFR is thus an impor-
tant conduit for relaying multiple signalling inputs. Many
“cross-talk” mechanisms have been described, including
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those employing metalloprotease-mediated shedding of
EGFR ligands. G protein-coupled receptors (GPCR)
transactivate EGFR in diverse cells, an interplay previously
thought to be largely EGFR ligand-independent. However,
building on observations that GPCR can also transacti-
vate EGFR via metalloprotease induction of EGF-like
ligands in several tumour cell types, Yan et al. have discov-
ered that ADAM10 promotes HB-EGF release in COS-7
and PC3 cancer cells. In parallel, Gschwind et al. have
demonstrated in head and neck cancer cells that GPCR
transactivation of EGFR is regulated by TACE cleavage of
AR, resulting in MAP kinase and AKT signalling, prolifera-
tion and cell migration. Interestingly, metalloprotease-
mediated GPCR-EGFR cross-talk has also been reported
in breast cancer [5]. Thus, oestrogens rapidly transacti-
vate EGFR to hyperactivate MAP kinase via G protein
coupled receptor (GPR30)-dependent promotion of HB-
EGF at the plasma membrane, an event that occurs in
oestrogen receptor positive and negative breast cancer
cells [5]. Of some further interest is insulin-like growth
factor receptor (IGFR), which induces EGFR activation via
metalloprotease-dependent release of AR or HB-EGF in
several tumour cell types [6]. IGFR-EGFR cross-talk is
certainly apparent in mammary epithelial cells, since EGFR
blockade abrogates IGFR-driven MAP kinase signalling
and primes apoptosis. However, it remains controversial
whether this cross-talk involves metalloprotease-mediated
EGFR ligand release [7] and studies investigating IGFR-
EGFR interactions are ongoing in breast cancer. While
the matrix metalloproteases MMP2 and MMP9 appear to
play a role in GPCR-mediated HB-EGF release, the full
profile of metalloproteases, including ADAMs, contributing
to EGFR transactivation and its end-points remains to be
defined in breast cancer.
Conclusion
Collectively the recent articles by Borrell-Pages et al, Yan
et al, and Gschwind et al. demonstrate that ADAMs are
important regulators of EGFR ligand shedding and EGFR
activation in tumour cells, also contributing to the produc-
tive “cross-talk” between diverse signalling pathways and
EGFR. Of particular interest is TACE/ADAM17, where
Borrell-Pages et al. have now demonstrated a critical role
in tumourigenesis, and EGFR signalling in breast cancer.
While their individual signalling role and cellular impact
remains to be defined, an increasing cohort of ADAMs are
prominent in breast tumours. Borrell-Pages et al. also
detected ADAM10 within normal and cancerous breast,
while ADAM12 is overexpressed in several breast cancer
cell lines [8] and ADAM9 is enriched in node positive
disease [9]. Thus, given the prevalence and emerging sig-
nalling importance of ADAMs in breast cancer, ADAM-
mediated ligand shedding may provide interesting new
avenues for therapeutic exploitation to abrogate EGFR
signalling, particularly since it is now clear that EGFR inhi-
bition has considerable potential to uncouple diverse mito-
genic inputs. Such therapies may confer important advan-
tages over existing anti-EGFR strategies, since ADAM-
mediated ectodomain shedding regulates many additional
proteins linked to signal transduction and neoplastic cell
behaviour. Thus, ADAMs can cleave cytokines, receptors
(erbB4, MET, NGFR, PDGFR, TNFR, IL receptor), addi-
tional ligands (neuregulins), IGF binding proteins, and
NOTCH signalling elements [10]. Future development of
ADAM-selective inhibitors will be essential if unwanted
side effects, previously noted with broad-spectrum metal-
loprotease inhibitors, are to be avoided.
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